Nearly two years after Takeda pulled its US marketing application for a vaccine against dengue fever, MSD has advanced a rival shot into phase 3. The international MOBILIZE-1 trial is looking at a ...
As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its newly acquired PD-1xVEGF drug as a new cornerstone of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback